William Love
Founder chez DESTINY PHARMA PLC
Fortune : 2 M $ au 31/03/2024
Profil
William Guy Love is the founder of Destiny Pharma Plc, a company founded in 1996.
He currently holds the title of Chief Scientific Officer & Executive Director at Destiny Pharma Plc.
In addition to his founding position, Dr. Love also held a former job as a Founding Member at Beam Alliance.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
DESTINY PHARMA PLC
6,83% | 18/10/2023 | 6 509 500 ( 6,83% ) | 2 M $ | 31/03/2024 |
Postes actifs de William Love
| Sociétés | Poste | Début |
|---|---|---|
| DESTINY PHARMA PLC | Founder | 04/03/1996 |
Anciens postes connus de William Love
| Sociétés | Poste | Fin |
|---|---|---|
Beam Alliance
 Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DESTINY PHARMA PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Beam Alliance
Beam Alliance Pharmaceuticals: MajorHealth Technology Beam Alliance is a French company that collaborates with the existing community of stakeholders to foster tangible policies and incentives for the discovery and development of novel antibacterial therapies and diagnostics. The private company is based in Paris, France. The company is aware of the problem arising from the lack of differentiation between different antimicrobials and has set up a dedicated scientific team, namely the Beam Task Force - E (BTF-E), to tackle the issue and propose solutions for better evaluating antimicrobial efficacy within a regulatory context. The company was founded by Florence Séjourné. | Health Technology |
